Niclosamide-d3

Niclosamide-d3 (BAY2353-d3) is deuterium labeled Niclosamide. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].

Product Specifications

CAS Number

[2665663-60-3]

Product Name Alternative

BAY2353-d3

UNSPSC

12352005

Target

Antibiotic; Isotope-Labeled Compounds; Parasite; STAT

Related Pathways

Anti-infection; JAK/STAT Signaling; Others; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Smiles

O=C(NC1=C([2H])C([2H])=C([N+]([O-])=O)C([2H])=C1Cl)C2=CC(Cl)=CC=C2O

Molecular Formula

C13H5D3Cl2N2O4

Molecular Weight

330.14

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19 (2) :245-95.|[3]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[4]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22 (14) :3458-66.|[5]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1 (9) :454-9.|[6]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48 (7) :2693-6.